

Edgar Filing: MILESTONE SCIENTIFIC INC/NJ - Form 10QSB

MILESTONE SCIENTIFIC INC/NJ  
Form 10QSB  
May 15, 2006

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-QSB

MARK ONE

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT  
OF 1934

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2006

OR

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE  
ACT OF 1934

FOR THE TRANSITION PERIOD FROM \_\_\_\_\_ TO \_\_\_\_\_

COMMISSION FILE NUMBER 001-14053

MILESTONE SCIENTIFIC INC.  
(Exact name of Registrant as specified in its charter)

DELAWARE 13-3545623  
-----  
State or other jurisdiction (I.R.S. Employer  
or organization) Identification No.)

220 SOUTH ORANGE AVENUE, LIVINGSTON, NEW JERSEY 07039  
-----

(Address of principal executive office) (Zip Code)

(973) 535-2717

(Registrant's telephone number, including area code)

CHECK WHETHER THE ISSUER (1) HAS FILED ALL REPORTS REQUIRED TO BE FILED  
BY SECTION 13 OR 15(d) OF THE EXCHANGE ACT DURING THE PAST 12 MONTHS (OR FOR  
SUCH SHORTER PERIOD THAT THE REGISTRANT WAS REQUIRED TO FILE SUCH REPORTS), AND  
(2) HAS BEEN SUBJECT TO SUCH FILING REQUIREMENTS FOR THE PAST 90 DAYS.  
YES  NO

INDICATE BY CHECK MARK WHETHER THE REGISTRANT IS A SHELL COMPANY (AS  
DEFINED IN RULE 12B-2 OF THE EXCHANGE ACT). YES  NO

AS OF MAY 15, 2006, THE ISSUER HAD A TOTAL OF 11,561,214 SHARES OF COMMON STOCK,  
\$.001 PAR VALUE, OUTSTANDING.

# Edgar Filing: MILESTONE SCIENTIFIC INC/NJ - Form 10QSB

## FORWARD LOOKING STATEMENTS

When used in this Quarterly Report on Form 10-QSB, the words "may", "will", "should", "expect", "believe", "anticipate", "continue", "estimate", "project", "intend" and similar expressions are intended to identify forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act regarding events, conditions and financial trends that may affect Milestone's future plans of operations, business strategy, results of operations and financial condition. Milestone wishes to ensure that such statements are accompanied by meaningful cautionary statements pursuant to the safe harbor established in the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties and that actual results may differ materially from those included within the forward-looking statements as a result of various factors. Such forward-looking statements should, therefore, be considered in light of various important factors, including those set forth herein and others set forth from time to time in Milestone's reports and registration statements filed with the Securities and Exchange Commission (the "Commission"). Milestone disclaims any intent or obligation to update such forward-looking statements.

2

MILESTONE SCIENTIFIC INC.

I N D E X

-----

### PART I. FINANCIAL INFORMATION

#### ITEM 1. Financial Statements (unaudited)

Condensed Balance Sheets

March 31, 2006 (Unaudited) and December 31, 2005

Condensed Statements of Operations

Three Months Ended March 31, 2006 and 2005 (Unaudited)

Condensed Statements of Changes in Stockholders' Equity (Deficiency)

Three Months Ended March 31, 2006 (Unaudited)

Condensed Statements of Cash Flows

Three Months Ended March 31, 2006 and 2005 (Unaudited)

Notes to Condensed Financial Statements

#### ITEM 2. Management's Discussion and Analysis or Plan of Operation

#### ITEM 3 Controls and Procedures

### PART II. OTHER INFORMATION

#### ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

Edgar Filing: MILESTONE SCIENTIFIC INC/NJ - Form 10QSB

ITEM 6. Exhibits

SIGNATURES

CERTIFICATIONS

3

MILESTONE SCIENTIFIC INC.  
CONDENSED BALANCE SHEETS

ASSETS

Current Assets:

Cash and cash equivalents

Accounts receivable , net of allowance for doubtful accounts of \$34,830  
in 2006 and \$27,117 in 2005

Royalty receivable

Inventories

Advances to contract manufacturer

Prepaid expenses

Total current assets

Investment in distributor, at cost

Equipment, net of accumulated depreciation of \$331,127 in 2006 and \$307,000 in 2005

Patents, net of accumulated amortization of \$24,802 in 2006 and \$19,090 in 2005

Other assets

Total assets

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:

Accounts payable

Accrued expenses

Deferred compensation payable to officers

Total current liabilities

Stockholders' Equity

Common stock, par value \$.001; authorized 50,000,000 shares; 11,594,547  
shares issued, 207,726 shares to be issued, and 11,561,214 shares  
outstanding in 2006; 11,550,479 shares issued, 207,726 shares to be  
issued, and 11,517,146 shares outstanding in 2005

Additional paid-in capital

Accumulated deficit

Treasury stock, at cost, 33,333 shares

Total stockholders' equity

Total liabilities and stockholders' equity

Edgar Filing: MILESTONE SCIENTIFIC INC/NJ - Form 10QSB

See Notes to Condensed Financial Statements

\* Derived from the audited financial statements as of December 31, 2005

4

MILESTONE SCIENTIFIC INC.  
 CONDENSED STATEMENTS OF OPERATIONS  
 THREE MONTHS ENDED MARCH 31, 2006 AND 2005  
 (Unaudited)

	March 31, 2006	Ma
	-----	-----
Product sales, net	\$ 1,560,919	\$
Royalty income	136,837	
	-----	-----
Total revenue	1,697,756	\$
	-----	-----
Cost of products sold	751,162	
Royalty expense	16,421	
	-----	-----
Total cost of revenue	767,583	
	-----	-----
Gross profit	930,173	
Selling, general and administrative expenses	1,479,714	
Research and development expenses	163,442	
	-----	-----
Total operating expenses	1,643,156	
	-----	-----
Loss from operations	(712,983)	
Other income		
Interest income	27,404	
	-----	-----
Total other income	27,404	
	-----	-----
Net loss	(685,579)	
Dividends applicable to preferred stock	-	
	-----	-----
Net loss applicable to common stockholders	\$ (685,579)	\$
	=====	=====
Loss per share applicable to common stockholders - basic and diluted	\$ (0.06)	\$
	=====	=====
Weighted average shares outstanding and to be issued - basic and diluted	11,741,578	=====
	=====	=====

Edgar Filing: MILESTONE SCIENTIFIC INC/NJ - Form 10QSB

See Notes to Condensed Financial Statements

5

MILESTONE SCIENTIFIC INC.  
 CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)  
 THREE MONTHS ENDED MARCH 31, 2006  
 (Unaudited)

	Common Stock		Additi Paid- Capit
	Shares	Amount	
Balance, January 1, 2006	11,758,205	\$ 11,758	\$ 57,
Common stock and options issued for payment of consulting services	8,491	9	
Common stock issued for payment of vendor services	35,577	36	
Common stock and options issued for payment of employee compensation			
Net loss			
Balance, March 31, 2006	11,802,273	\$ 11,803	\$ 57,

	Treasury Stock	Total
Balance, January 1, 2006	\$ (911,516)	\$ 6,318,206
Common stock and options issued for payment of consulting services		45,819
Common stock issued for payment of vendor services		37,000
Common stock and options issued for payment of employee compensation		8,239
Net loss		(685,579)
Balance, March 31, 2006	\$ (911,516)	\$ 5,723,685

See Notes to Condensed Financial Statements

6

MILESTONE SCIENTIFIC INC.  
 CONDENSED STATEMENTS OF CASH FLOWS

Edgar Filing: MILESTONE SCIENTIFIC INC/NJ - Form 10QSB

THREE MONTHS ENDED MARCH 31, 2006 AND 2005  
(Unaudited)

	20
	-----
Cash flows from operating activities:	
Net loss	\$ (685,
Adjustments to reconcile net loss to net cash used in operating activities:	
Depreciation expense	24,
Amortization of patents	5,
Common stock and options issued for compensation, consulting, and vendor services	91,
Other	1,
Bad debt expense	7,
Changes in operating assets and liabilities:	
(Increase) in accounts receivable	(158,
Decrease in royalty receivable	48,
Decrease in inventories	25,
(Increase) in advances to contract manufacturer	(143,
Decrease (increase) in prepaid expenses	11,
Decrease in other assets	2,
Increase in accounts payable	122,
Increase (decrease) in accrued expenses	158,
Increase in deferred compensation	43,
	-----
Net cash used in operating activities	(445,
	-----
Cash flows from investing activities:	
Payment for capital expenditures	-
Payment for patent rights	(2,
	-----
Net cash used in investing activities	(2,
	-----
Cash flows from financing activities:	
Proceeds from equity financing, net	-
	-----
Net cash provided by financing activities	-
	-----
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(447,
Cash and cash equivalents at beginning of period	2,892,
	-----
Cash and cash equivalents at end of period	\$ 2,444,
	=====

See Notes to Condensed Financial Statements

# Edgar Filing: MILESTONE SCIENTIFIC INC/NJ - Form 10QSB

(Unaudited)

Supplemental schedule of noncash investing and financing activities:

On January 27, 2005, Milestone issued 43,424 shares valued at \$70,000 to the Company's outside director of clinical affairs, pursuant to a technology agreement to provide Milestone with patent rights.

See Notes to Condensed Financial Statements

8

## MILESTONE SCIENTIFIC INC. NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

### Note 1 - Summary of accounting policies

The unaudited financial statements of Milestone Scientific Inc. (the "Company") have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.

These unaudited financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2005 included in Milestone's Annual Report on Form 10-KSB. The accounting policies used in preparing these unaudited financial statements are the same as those described in the December 31, 2005 financial statements.

In the opinion of Milestone, the accompanying unaudited financial statements contain all adjustments (consisting of normal recurring entries) necessary to fairly present Milestone's financial position as of March 31, 2006 and the results of its operations for the three months ended March 31, 2006 and 2005.

The results reported for the three months ended March 31, 2006 are not necessarily indicative of the results of operations which may be expected for a full year.

### Note 2 - Private placement

On April 4, 2005 Milestone completed a \$2,999,996 private placement of 101,044 units to accredited investors. Each unit consisted of 10 shares of Common Stock and two Warrants. Each Warrant entitles the holder to purchase a share of Common Stock at \$4.89 per share through the close of business on February 16, 2009. I-Bankers Securities, Inc. acted as

## Edgar Filing: MILESTONE SCIENTIFIC INC/NJ - Form 10QSB

Placement Agent for Milestone in this transaction and received a fee of \$209,978 and 101,044 Warrants identical in terms to those issued to the investors. The units, which are restricted securities and bear a restrictive legend, are subject to stop transfer restrictions. Net proceeds to Milestone after commissions and other expenses were \$2,655,659.

### Note 3 - Royalty receivable

Royalty receivable represents the royalty due from United Systems Inc, the licensee of Milestone's proprietary consumer dental whitening product, which is sold under Milestone's distributor's trademark of Ionic White(TM). The royalty receivable of \$136,838 was received on April 28, 2006.

### Note 4 - Inventories

Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or market.

9

### Note 5 - Advances to contract manufacturer

Advances to contract manufacturer represent deposits to the Company's contract manufacturer to fund future inventory purchases. The balance of advances as of March 31, 2006 totaled \$1,163,520.

### Note 6 - Basic and diluted net loss per common share

Milestone presents "basic" earnings (loss) per common share and, if applicable, "diluted" earnings per common share pursuant to the provisions of Statement of Financial Accounting Standards No. 128, "Earnings per Share" ("SFAS 128"). Basic earnings (loss) per common shares is calculated by dividing net income or loss applicable to common stock by the weighted average number of common shares outstanding and to be issued during each period. The calculation of diluted earnings per common share is similar to that of basic earnings per common share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options, warrants, and the conversion of notes payable and preferred stock were issued during the period.

Since Milestone had net losses for the three months ended March 31, 2006 and 2005, the assumed effects of the exercise of outstanding stock options and warrants and the conversion of preferred stock into common stock were not included in the calculation as their effect would have been anti-dilutive. Such outstanding options, warrants and preferred stock totaled 3,605,085 and 3,595,475 at March 31, 2006 and 2005, respectively.

### Note 7 - Significant Customer

Milestone had one foreign customer who accounted for approximately 25.3% and 21.9% of its net sales for the three months ended March 31, 2006 and 2005, respectively. At March 31, 2006, receivables from this customer were approximately 77% of Milestone's total accounts



## Edgar Filing: MILESTONE SCIENTIFIC INC/NJ - Form 10QSB

receivable.

### Note 8 - Employee Stock Option Plan

Milestone adopted SFAS No. 123R, "Share-Based Payment, an Amendment of FASB Statement No. 123", under the modified-prospective transition method on January 1, 2006. SFAS No. 123R requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statements over the service period, as an operating expense, based on the grant-date fair values. Pro-forma disclosure is no longer an alternative. As a result of adopting SFAS 123R, the Company recognizes as compensation expense in its financial statements the unvested portion of existing options granted prior to the effective date and the cost of stock options granted to employees after the effective date based on the fair value of the stock options at grant date. Prior to the adoption of SFAS No. 123R, the Company accounted for its stock option plans using the intrinsic value method of accounting prescribed by APB Opinion No. 25.

As of March 31, 2006, there were 244,167 outstanding options granted under the Milestone 1997 Stock Option Plan and 167,000 outstanding options granted under the Milestone 2004 Stock Option Plan. As a result of adopting SFAS No. 123R, the Company recognized \$3,238 in share-based compensation expense and a corresponding increase in net loss for the three months ended March 31, 2006. This share-based compensation expense had minimal impact on the Company's basic and diluted earnings per share.

The following table illustrates net loss and loss per share applicable to common stockholders for the three months ended 2005, if Milestone had applied SFAS No. 123R. No options were granted during the three months ended March 31, 2006.

10

Net loss, as reported	\$	(878,943)
Deduct total stock-based employee compensation expenses determined under the fair value based method for all awards		201,172
		-----
Net loss, pro forma	\$	(1,080,115)
		=====
Loss per share applicable to common stock holders:		
Basic and diluted		
As reported	\$	(0.09)
		=====
Pro forma	\$	(0.11)
		=====

The fair value of each option granted is estimated on the date of the grant using the Black-Scholes option pricing model with the following assumptions used for the grants in the three months ended March 31, 2005: dividend yield of 0%; expected volatility of 119.42%; risk free interest rate of 3.87%; and expected lives of 5 years.

Expected volatilities are based on historical volatility of the company's common stock. The company uses historical data to estimate

## Edgar Filing: MILESTONE SCIENTIFIC INC/NJ - Form 10QSB

option exercise and employee termination within the valuation model. The expected term of the option granted is estimated based on historical behavior of employees and represents the period of time that options granted are expected to be outstanding. A summary of option activity under the plan as of March 31, 2006, and changes during the three months then ended is presented below:

OPTIONS -----	NUMBER OUTSTANDING -----	WEIGHTED AVERAGE EXERCISE PRICE -----	WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE (YEARS) -----	AGGREGATE INTRINSIC VALUE -----
Outstanding, January 1, 2006	453,167	\$2.63	3.6	\$ 0
Granted	--	--	--	--
Exercised	--	--	--	--
Forfeited or expired	42,000	3.16	3.0	0
Outstanding, March 31, 2006	411,167	2.57	3.7	0
Exercisable, March 31, 2006	341,055	2.48	3.7	0

As of March 31, 2006, there was \$79,517 of total unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the plan. That cost is expected to be recognized over a weighted average period of one year.

### Note 9 - Agreements to Issue Common Stock and Stock Options

On March 18, 2005, Milestone issued to Ionic White, Inc., its marketing partner for a consumer tooth whitening product, 3-year options to purchase 100,000 shares of Milestone common stock at \$4.89 per share. The options are not exercisable unless the marketing partner purchases at least 2,000,000 starter kits for the registrant's consumer tooth whitening system during the twelve month period beginning July 1, 2005. If 2,000,000 starter kits are purchased during that period, options to purchase 10,000 shares become exercisable. If 2,500,000 starter kits are purchased during that period, options to purchase an aggregate of 50,000 shares become exercisable. If 3,000,000 starter kits are purchased during that period, options to purchase all 100,000 shares become exercisable. Upon the options becoming exercisable, Milestone will recognize sales discounts based on the then fair value of the options.

11

Under a previous agreement, Ionic White, Inc., agreed to purchase at \$3.00 per share 500,000 shares of Milestone common stock in quarterly installments of 125,000 shares within 10 days after the end of each of the four fiscal quarters commencing July 1, 2005. Milestone is not required to sell these shares unless Ionic White has purchased at least 625,000 starter kits in the first quarter, at least 1,250,000 starter kits in the first two quarters and at least 1,875,000 starter kits in the first three quarters. Further, at Milestone's option, all shares previously purchased must be returned to Milestone and all monies paid to Milestone returned to Ionic White if it has not purchased an aggregate of at least 3,000,000 starter kits for the twelve-month

## Edgar Filing: MILESTONE SCIENTIFIC INC/NJ - Form 10QSB

period ending June 30, 2006.

On September 30, 2005, this agreement was amended to defer, for an additional quarter, the commencement date for Ionic White's commitment to purchase stock. On December 21, 2005, the commencement date for stock purchase was further deferred until January 1, 2006. On March 31, 2006, the commencement date for stock purchase was further deferred for another quarter. At March 31, 2006, no shares have been purchased by Ionic White.

On August 12, 2005, Milestone engaged a special marketing and sales consultant to aid in the international sale and distribution of CoolBlue(TM) Wand dental enhancement system, particularly in its applications for professional tooth whitening. As part of the compensation for a two-year consulting service, Milestone issued 40,000 shares of common stock valued at \$100,000 to the consultant.

In addition, if as a result of the consultant's efforts, Milestone is able to establish distribution relationships, on terms and conditions satisfactory to Milestone, with one of the four top world-wide distributors of dental products, or other major distributors as are acceptable to Milestone, and Milestone sells such distributors \$3,000,000 of product within 18 months commencing August 12, 2005, Milestone will pay the consultant a \$20,000 bonus, in shares of Milestone common stock, valued based on the then current market value. At March 31, 2006, Milestone has not entered into any distribution agreement with any of the distributors.

12

### ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION.

#### OVERVIEW

The following discussion of our financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements included elsewhere in this Form 10-QSB. This discussion may contain forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, such as those set forth in our Form 10-KSB for the year ended December 31, 2005.

Milestone has succeeded in improving its liquidity by acquiring the capital necessary to grow our business and seize the market opportunity that our proprietary products have created. During 2005 and continuing in the first quarter of 2006, we have grown our revenue base both with our existing product lines and the introduction of new products, as evidenced by the eighth consecutive quarter of total revenue growth when compared to the same period in the previous year.

Most of our revenues continue to be generated through sales of our CompuDent system and the Wand disposable handpiece used with that system. Revenues have been earned domestically and internationally through sales in more than 25 countries. While we are growing our revenues throughout the world, domestic CompuDent and handpiece sales have provided a growing portion of our revenues relative to international sales. This is an important measure as it validates the investment made in our domestic sales distribution, particularly as handpiece revenues increased as a result of the increase in CompuDent users.

## Edgar Filing: MILESTONE SCIENTIFIC INC/NJ - Form 10QSB

Also, we enjoy significantly higher margins on domestic sales compared to the lower per unit revenues we receive from our wholesale based international distribution network. We anticipate that our growing base of new customers will generate increased future sales of our disposable handpiece products. We believe that our ownership of the SafetyWand technology, in light of OSHA regulations issued pursuant to recent federal and state government legislation, mandating needle stick safety standards, positions us to become a leading provider for dentists and other health care professionals in the administration of local anesthesia, thereby providing further revenue growth opportunities.

During the first quarter, we took steps to enhance the efficiency and effectiveness of our domestic sales operation. We reduced the total headcount by one national sales manager, one sales trainer and several under-performing inside sales representatives. Our goal is to become, at minimum, cash neutral from our domestic sales of CompuDent units and CoolBlue Whitening Kits. In March 2006, this goal was accomplished.

In March 2005 we launched, through widely broadcast infomercials, our consumer tooth whitening product. The product also appeared in retail outlets in September 2005, including Walgreen's, Target and Linens and Things. The consumer tooth whitening market is one of the fastest growing dental market places. We believe it provides significant additional revenue opportunities. Towards the end of 2005, Milestone Scientific began a controlled market launch of its CoolBlue Professional Tooth Whitening System, which targets the \$1 billion global professional teeth whitening market. As with other Milestone products, the CoolBlue system is designed to maximize long-term revenues from disposable per-patient kits that are utilized in the whitening treatment process. While revenues in the first quarter were not significant, we believe the product will allow a higher degree of market penetration, which will also provide additional selling opportunities for our CompuDent system.

We continue development work on two important technologies. The Single Tooth Anesthetic (STA) delivery system, currently in development, will allow dentists to perform a predictable single tooth anesthetic injection to achieve total tooth anesthesia, as a primary injection. This will become an invaluable tool as many consider this type of injection to be the most important injection for the dentist and preferred by patients. The expected market introduction for the STA device is early 2007.

13

We also continue development efforts on our CompuFlo technology, which is first being targeted for spinal anesthesia, including for epidural anesthesia. The Company has contracted with an outside firm to identify additional clinical applications for this technology in the all important medical space.

Selling, general and administrative expenses for the first quarter decreased, reflecting stabilization of the hiring and related costs for the domestic sales organization as well as other cost containment programs. Related research and development expenses for STA and CompuFlo totaled \$163,442 for the period. While this total represented 10% of the total operating expenses, the continued investment in these development programs is crucial for our future success.

The following table shows a breakdown of our product sales (net), domestically and internationally, by product category, and the percentage of product sales (net) by each product category:

Edgar Filing: MILESTONE SCIENTIFIC INC/NJ - Form 10QSB

	Three Months Ended	
	2006	
DOMESTIC		
CompuDent	\$ 221,794	21.4%
Handpieces	741,654	71.6%
Other	72,547	7.0%
	-----	-----
Total Domestic	\$1,035,995	100.0%
	-----	-----
INTERNATIONAL		
CompuDent	\$ 231,908	44.2%
Handpieces	239,146	45.5%
Other	53,870	10.3%
	-----	-----
Total International	\$ 524,924	100.0%
	-----	-----
DOMESTIC/INTERNATIONAL ANALYSIS		
Domestic	\$1,035,995	66.4%
International	524,924	33.6%
	-----	-----
Totals	\$1,560,919	100.0%
	=====	=====

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to accounts receivable, inventories, stock-based compensation, and contingencies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates under different assumptions or conditions.

14

Inventory

Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or market.

Impairment of Long-Lived Assets

We review long-lived assets for impairment whenever circumstances and situations change such that there is an indication that the carrying

## Edgar Filing: MILESTONE SCIENTIFIC INC/NJ - Form 10QSB

amounts may not be recovered.

### Revenue Recognition

Sales revenue is recognized when title passes at the time of shipment and collectibility based on a sales arrangement and the agreed upon price is reasonably assured. Royalty revenue is recognized based upon royalty reports from the licensee.

### Stock-Based Compensation

Effective January 1, 2006, the Company adopted SFAS No. 123R, "Share-Based Payment, an Amendment of FASB Statement No. 123". Prior to January 2006, the Company accounted for stock-based compensation by using the intrinsic value method under APB Opinion No. 25. As required by SFAS No. 123R, the Company recognizes in the statement of operations the grant-date fair value of stock options issued to employees and non-employees.

### RESULTS OF OPERATIONS

The results of operations for the three months ended March 31, 2006 reflect a stable growth of our user base, well controlled expenditures necessary to expand our market, and significant investment in new product development. The net loss for the three months ended March 31, 2006 represents a 22% decrease from the same period in 2005.

The following table sets forth, for the periods presented, statement of operations data as a percentage of revenues. The trends suggested by this table may not be indicative of future operating results.

15

	Three Months Ended March 31,		
	2006		
Products sales, net	\$ 1,560,919	92%	\$ 1,
Royalty income	136,837	8%	
Total revenue	1,697,756	100%	1,
Cost of products sold	751,162	44%	
Royalty expense	16,421	1%	
Total cost of revenue	767,583	45%	
Gross Profit	930,173	55%	
Selling, general and administrative expenses	1,479,714	87%	1,
Research and development expenses	163,442	10%	
Total operating expenses	1,643,156	97%	1,

Edgar Filing: MILESTONE SCIENTIFIC INC/NJ - Form 10QSB

Loss from operations	(712,983)	-42%
Other income - interest	27,404	2%
Net loss	\$ (685,579)	-40%

Three Months ended March 31, 2006 compared to three months ended March 31, 2005

Total revenues for the three months ended March 31, 2006 and 2005 were \$1,697,756 (product sales of \$1,560,919 and royalty income of \$136,837) and \$1,457,903, respectively. The \$103,016 or 7% increase in net product sales is primarily related to a \$77,263 or 12% increase in domestic handpiece sales and \$55,957 in worldwide whitening product sales, which did not exist in 2005. Domestic CompuDent sales decreased \$105,894 or 32% which was partially off-set by an increase in international CompuDent sales of \$58,841 or 34%. Worldwide handpiece sales increased \$47,828 or 5%. This increase shows the effect of an expanded base of CompuDent units in service and represents a continuing increase in the revenue stream from the disposable Wand handpieces. The amount of \$136,837 or 8% of total revenue in 2006 is royalty income from granting United Systems Inc. a license to manufacture, market, and sublicense the Ionic White(TM) to the consumer market.

Cost of products sold for the three months ended March 31, 2006 and 2005 were \$751,162 and \$714,706, respectively. The \$36,456 or 5% increase is primarily attributable to the additional cost of goods sold for the higher revenues previously discussed. Royalty expense related to the royalty income from the sales of the Ionic White(TM) tooth whitening system was \$16,421 for the three months ended March 31, 2006. This expense did not exist in the same period in 2005.

For the three months ended March 31, 2006, Milestone generated a gross profit of \$930,173 or 55% as compared to a gross profit of \$743,197 or 51% for the same period in 2005. Excluding the net royalty income (net of royalty expense) of \$120,416, which has a gross profit of 88%, gross profit of products sales was \$809,757 or 52% in 2006. It is comparable with gross profit in the same period in 2005.

Selling, general and administrative expenses for the three months ended March 31, 2006 and 2005 were \$1,479,714 and \$1,601,693, respectively. The \$121,979 or 8% decrease is attributable primarily to a decrease in salaries, travel and our outsourced warehousing function which were partially off-set by increases in commissions, hiring and related employee expenses and advertising media placement.

16

Research and development expenses for the three months ended March 31, 2006 and 2005 were \$163,442 and \$31,545, respectively. These costs are primarily associated with the development of Milestone's Single Tooth Anesthetic (STA) delivery system and continuing efforts on the CompuFlo(TM) technology.

Loss from operations for the three months ended March 31, 2006 and 2005 was \$712,983 and \$890,041, respectively. The \$177,058 or 20% decrease in loss from operations is the result of internal cost containment programs related to our domestic sales operation and controlled expenditures necessary to expand our market and to carry out our operations.

Interest income of \$27,404 was earned in the three months ended March

## Edgar Filing: MILESTONE SCIENTIFIC INC/NJ - Form 10QSB

31, 2006 compared to \$11,098 earned for the same period in 2005. The increase of \$16,306 or 147% in interest income is the result of increased average cash balance and increased interest rate in 2006.

For the reasons explained above, net loss for the three months ended March 31, 2006 was \$685,579 as compared to a net loss of \$878,943 for the same period in 2005. The \$193,364 or 22% decrease in net loss is primarily a result of the increased total revenue and the increased interest income which are partially offset by the increased operating expenses.

17

### LIQUIDITY AND CAPITAL RESOURCES

Milestone incurred net losses of approximately \$686,000 and \$879,000 and negative cash flows from operating activities of approximately \$445,000 and \$781,000 during the three months ended March 31, 2006 and 2005, respectively. Milestone improved its liquidity position with the private placement of Units completed in April and June 2005, as discussed below.

#### Private Placement

On April 4, 2005 Milestone completed a \$2,999,996 private placement of 101,044 units to accredited investors. Each unit consisted of 10 shares of Common Stock and two warrants (the "Unit" or "Units"). Each warrant entitles the holder to purchase a share of Common Stock at \$4.89 per share through the close of business on February 16, 2009 (the "Warrant" or "Warrants"). I-Bankers Securities, Inc. acted as Placement Agent for Milestone in this transaction and received a fee of \$209,978 and 101,044 Warrants identical in terms to those issued to the investors. The Units, which are restricted securities and bear a restrictive legend, are subject to stop transfer restrictions. Net proceeds to Milestone, after commissions and other expenses, were \$2,655,659.

On June 30, 2005 Milestone completed a \$847,960 private placement of 34,000 Units. Dynamic Decisions acted as Placement Agent for Milestone in this transaction and received a fee of \$50,878 and 600 Units, which are substantially the same form as those issued to the investors. Total proceeds from this private placement, after commissions and other expenses, were \$797,054.

### CASH FLOW RESULTS

As of March 31, 2006, Milestone had cash and cash equivalents of \$2,444,810 and working capital of \$4,631,878.

For the three months ended March 31, 2006, Milestone's net cash used in operating activities was \$445,064. This was attributable primarily to a net loss of \$685,579 adjusted for noncash items of \$130,731 (of which \$24,300 was depreciation expense; \$5,712 was amortization of patents; \$91,058 was stock and options issued for compensation, consulting, and vendor services; \$1,918 was other; and, \$7,743 was bad debt expense); a \$158,651 increase in accounts receivable; a \$48,864 decrease in royalty receivable; a \$25,656 decrease in inventories; a \$143,857 increase in advances to contract manufacturer; a \$11,040 decrease in prepaid expenses; a \$2,514 decrease in other assets; a \$280,885 increase in accounts payable and accrued expenses; and, a \$43,333 increase in deferred compensation.

For the three months ended March 31, 2006, Milestone used \$2,805 in investing activities. This was due to legal fees related to new patent



applications.

Management believes that it has sufficient resources to meet its obligations over the next twelve months.

18

ITEM 3. CONTROLS AND PROCEDURES

- a) Evaluation of Disclosure Controls and Procedures. Milestone's management, with the participation of the Chief Executive Officer and the Chief Financial Officer, carried out an evaluation of the effectiveness of Milestone's "disclosure controls and procedures" (as defined in the Securities Exchange Act, Rule 13a-15(e) and 15d-15(e)). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that Milestone's disclosure controls and procedures were effective, as of the date of their evaluation, for purposes of recording, processing, summarizing and timely reporting material information required to be disclosed in reports filed by Milestone under the Securities Exchange Act of 1934.
- b) Changes in Internal Control over Financial Reporting. There were no changes in our internal controls over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, Milestone's internal control over fiscal reporting.

19

PART II

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Recent Sales of Unregistered Securities

In the quarter ended March 31, 2006, Milestone issued total 44,068 shares valued at \$46,000 to two vendors, one in satisfaction of an agreement to provide Milestone with exhibition facilities and another for payables owed in connection with purchased goods.

The shares were sold to accredited investors, bore a restrictive legend and were exempt from registration pursuant to s.s. 4.2 and 4.6 of the Securities

Edgar Filing: MILESTONE SCIENTIFIC INC/NJ - Form 10QSB

Act of 1933, as amended.

ITEM 6. EXHIBITS

The following exhibits are filed herewith:

- 31.1 Chief Executive Officer Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Chief Financial Officer Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1 Chief Executive Officer Certification pursuant to section 906 of the Sarbanes-Oxley Act of 2002.
- 32.2 Chief Financial Officer Certification pursuant to section 906 of the Sarbanes-Oxley Act of 2002.

20

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MILESTONE SCIENTIFIC INC.  
-----

Registrant

/s/Leonard Osser  
-----

Leonard Osser  
Chairman and Chief Executive Officer

/s/Rosaline Shau  
-----

Rosaline Shau  
Chief Financial Officer

Dated: May 15, 2006

21